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Abstract 
Background:  The  number  of  genetic  association  studies  is  increasing  exponentially. 
Nonetheless, genetic association reports are prone to potential biases which may influence 
the reported outcome. 
Aim: We hypothesized that positive outcome for a determined polymorphism might be 
over-reported across genetic association studies analysing a small number of polymorphisms, 
when compared to studies analysing the same polymorphism together with a high number of 
other polymorphisms. 
Methods: We systematically reviewed published reports on the association of glutathione 
s-transferase (GST) single-nucleotide polymorphisms (SNPs) and cancer outcome.  
Result: We identified 79 eligible trials. Most of the studies examined the GSTM1, theGSTP1 
Ile105Val mutation, and GSTT1polymorphisms (n = 54, 57 and 46, respectively). Studies an-
alysing one to three polymorphisms (n = 39) were significantly more likely to present positive 
outcomes, compared to studies examining more than 3 polymorphisms (n=40) p = 0.004; this 
was particularly evident for studies analysing the GSTM1polymorphism (p =0.001). We found 
no significant associations between journal impact factor, number of citations, and probability 
of publishing positive studies or studies with 1-3 polymorphisms examined.  
Conclusions: We propose a new subtype of publication bias in genetic association studies. 
Positive results for genetic association studies analysing a small number of polymorphisms (n 
= 1-3) should be evaluated extremely cautiously, because a very large number of such studies 
are inconclusive and statistically under-powered. Indeed, publication of misleading reports 
may affect harmfully medical decision-making and use of resources, both in clinical and 
pharmacological development setting. 
Key words: single-nucleotide polymorphisms, genetic association studies, publication-bias, litera-
ture bias, translational research. 
Introduction 
Genetic association studies investigate the rela-
tionship  between  gene  polymorphisms  and  risk  of 
disease  or  treatment  outcome.  Furthermore,  due  to 
advances  in  molecular  targeted  treatment  technolo-
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gies and the continual expansion of translational re-
search, genetic association studies play a key role in 
the  development  of  new  therapeutical  targets.  For 
these reasons the number of genetic association stud-
ies is increasing rapidly and this trend is expected to 
accelerate  due  to  the  availability  of  mapped  sin-
gle-nucleotide  polymorphisms  (SNP)  in  the  human 
genome and advances in genotyping technologies [1].  
However, despite the number of genetic associa-
tion  studies  being  expected  to  grow  exponentially 
over the next decade, no clear criteria are available to 
assess the credibility of these reports. Are all statistical 
significant medical reports, on SNP studies, reliable 
enough  to  drive  firm  conclusions  and  trig  clini-
cal/therapeutical applications?  
Positive-outcome (also known as “publication”) 
bias refers to the greater likelihood of a study with 
positive results to be published compared with stud-
ies  with  negative  results  [2,3].  Publication  bias 
(“false-positive” reporting) is a particular threat to the 
credibility of the literature, including genetic associa-
tion studies, since it may affect decision-making both 
in clinical and pharmacological development settings.  
Biologists, researchers and physicians are actu-
ally called to deal with manuscripts of translational 
medicine  research  in  their  daily  life.  However,  no 
parameters are actually available to orient them in a 
correct interpretation of potential misleading sources 
of literature-bias.  
Based  on  the  over  mentioned  reflections  and 
considering  the  following  three  facts:  1)  reviewer’s 
and  editor’s  decision  about  publication  of  manu-
scripts are influenced by positive findings [2,3,4]; 2) 
positive studies are more possible to be published in 
journals with higher impact factor (IF) [3,5] and may 
be cited more often than negative studies [6,7]; 3) null 
papers  are  typically  given  low  publication  priority 
scores and may not be accepted for publication [2], we 
hypothesized that the pressure for publication among 
authors and the fierce competition for acceptance in 
leading  journals  [3,4]  may  lead  authors  firstly,  to 
perform studies with few polymorphisms, which are 
less expensive, need less time to complete and  sec-
ondly,  to  submit  for  publication  only  those  studies 
with positive outcome. 
 Is it the case? If yes, what about the impact of 
this phenomenon on medical literature? How positive 
compared to negative reports correlate with publica-
tion differences in impact factor journals or citation 
frequency? 
In our study, we thereafter tested the hypothesis 
that  a  positive  outcome  for  a  determined  polymor-
phism might be over reported across genetic associa-
tion  studies  analysing  a  small  number  of  polymor-
phisms,  when  compared  to  studies  analysing  the 
same polymorphism together with a high number of 
other  polymorphisms.  We  also  tried  to  assess  any 
differences  in  journal  impact  factor  or  citation  fre-
quency among positive versus negative reports.  
Due to the high number of published reports on 
the  association  of  GST  polymorphisms  and  cancer 
outcome (mainly colorectal, breast, and lung malig-
nancy) SNPs for GST polymorphisms were used as a 
substrate for analyses.  
Materials and Methods 
Search strategy and eligibility criteria 
We electronically searched the PubMed medical 
literature  database and ISI Web of Science from in-
ception to June 1, 2009, without language restrictions, 
using  the  following  keyword  combinations:  (gluta-
thione s-transferase OR GST OR GSTT1 OR GSTM1 
OR GSTP1) AND (polymorphism OR polymorphisms 
OR SNP OR mutation) AND (cancer OR malign* OR 
carcinoma  OR  tumor  OR  tumour).  The  electronic 
search was supplemented by a manual review of the 
references of included studies.  
The studies selected for our analysis had to meet 
the following criteria: (a) investigate the association 
between at least of one GST SNP: and cancer outcome; 
and (b) include only patients with solid tumours. 
We excluded case-control studies that examined 
the role of GST polymorphisms on cancer risk, studies 
that included patients with hematologic malignancies 
and  studies  that  investigated  the  role  of  GST  poly-
morphisms on pharmacokinetics of specific drugs.  
Two  investigators  independently  reviewed  all 
potentially relevant articles to determine whether an 
article  met  the  inclusion  criteria,  and  disagreement 
was resolved by discussion between the investigators. 
Data extraction 
We  abstracted  the  following  information  from 
eligible  trials:  authors’  name,  year  of  publication, 
country of origin, type of cancer, sample size, number 
of polymorphisms tested and results of the study. 
Studies were divided into two categories based 
on  the  results  reported:  positive  or  negative  study. 
Since there is no standardized definition of positive 
results [8], the following definitions for positive and 
negative studies were used in our study:  
A study was defined as “positive” if it reported 
any statistical significant difference for any of the GST 
polymorphisms for at least one of the following out-
come measures: overall survival or disease recurrence 
or response to treatment. In the case of lack of a clear 
definition, or threshold, for statistical significant dif-Int. J. Med. Sci. 2011, 8 
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ference, we defined “significance” as the presence of a 
P-value  of  <0.05  or  another  effect  metric  with  95% 
confidence interval (C.I.) that fell entirely on one side 
of the null. A study was defined as negative if there 
was  no  statistically  significant  difference  detected 
between a determined GST polymorphisms and any 
of these outcomes. 
Regarding number of polymorphisms examined, 
eligible studies were divided into two groups: those 
which  examined  the  association  between  1-3  poly-
morphisms  and  cancer  outcome  and  those  which 
examined  the  association  of  more  than  3  polymor-
phisms. 
The Impact Factor (IF) of each journal was ex-
tracted  from  Journal  Citation  Reports  (Institute  for 
Scientific  Information,  JCR-ISI)  [9].  When  a  journal 
was not included in the citation index, we set 0 as IF.  
The number of citations was obtained though the 
Science Citation Index [10]. For each published article, 
all citations of that article from publication to the time 
of the search were identified. The number of citations 
per year from the year of publication to the study pe-
riod  was  calculated  for  each  article  (citations  per 
year). 
Statistical analysis 
Associations  were  tested  using  the  chi-square 
statistic or Fisher’s exact test with significance set at P 
< 0.05. The null hypothesis is that there is no differ-
ence  in  the  proportions  of  positive  and  negative 
studies  analysing  a  determined  polymorphisms  be-
tween the studies examining it within 1-3 polymor-
phisms versus studies examining the same polymor-
phism among more than 3 polymorphism. 
Since  the  distribution  of  IF  and  citation  fre-
quency  were  not  normal  (Shapiro-Wilk  test  <  0.05) 
[11],  we  used  nonparametric  tests  (Mann-Whitney 
tests)  [12]  to  study  the  difference  in  IF  and  in  fre-
quency of citations per year between groups. 
To  better  examine  the  possibility  of  a  bias  for 
positive  results  in  studies  examined  1-3  polymor-
phisms, logistic regression analysis, with adjustment 
for sample size, was used to calculate the odds ratio 
(OR) of reporting positive results in 2 study groups. 
All statistical analyses were done using the SPSS 
software (SPSS Inc., Chicago, IL, USA, version 11.5). 
All tests were two-sided with a significance level of 
0.05. 
Results 
Description of studies 
A  total  of  4695  studies  were 
identified  from  the  combined 
searches. We scanned titles and ab-
stracts  for  mention  of  GST  poly-
morphisms  associated  with  cancer 
outcome  in  either  the  title  or  the 
abstract.  We  retrieved  121  poten-
tially  eligible  articles  in  full  text 
[Figure 1]. 
 
 
 
Figure 1. Flowchart diagram of study 
selection. 
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A total of 79 articles that fulfilled the inclusion 
criteria were found [13-91]. A total of 10 GST poly-
morphisms were analysed: GSTM1, GSTP1 Ile105Val, 
GSTP1  Ala114Val,  GSTP1  Thr110Ser,  GSTP1 
Asp147Tyr, GSTT1, GSTM3, GSTA1, GSTO1, GSTO2. 
Of  those,  39  examined  1-3  polymorphisms 
[13,14,16,19,20,23,24,26-28,31,36,37,39-41,45,46,48,50,5
3,56,60-62,64,65,68,69,72-74,76-79,81,89,91]  and  40 
more than 3 polymorphisms [15,17,18,21,22,25,29,30, 
32-35,38,42-44,47,49,51,52,54,55,57-59,63,66,67,70,71,75
,80,82-88,90]. Fifty four studies examined the GSTM1 
polymorphism  [13,14,16,17,19-27,30-33,35,37,38,43-46, 
48,49,51-63,65,68,69,70,72-75,77,78,82,83,85-87],  57  the 
GSTP1  Ile105Val  polymorphism  [13-16,18,21,22,26, 
28-30,32-49,51-55,57-61,64,66,67,71,74,76-85,87-90],  46 
the  GSTT1  polymorphism  [13,14,16,17,19, 
21-23,25,27,32,33,35,37,38,43-46,48-63,65,70,72,74,75,77
,78,82,83,85,87]. Only a small number of reports were 
available for other polymorphisms: GSTP1 Ala114Val 
(n=7)  [15,32,40,42,66,80,85],  GSTP1  Thr110Ser  (n=1) 
[15],  GSTP1  Asp147Tyr  (n=1)  [15],  GSTM3  (n=2) 
[26,63], GSTA1 (n=1) [91], GSTO1 (n=1) [38], GSTO2 
(n=1) [44].  
Single studies characteristics for each of the 79 
eligible  studies  are  reported  in  the  appendix  Table, 
while  general  characteristics  for  the  eligible  studies 
are summarized in Table 1.  
Association between the outcome of studies 
and number of polymorphisms tested  
 When  a  given  polymorphism  was  analysed, 
studies  reporting  1-3  polymorphisms  were  signifi-
cantly more likely to present positive outcomes (n= 
29;  74%)  compared  to  studies  evaluating  the  poly-
morphism across more than 3 polymorphisms (n= 17; 
42.5%) (P-value = 0.004); this was particularly evident 
for  studies  analysing  GSTM1  polymorphism  (n=  13 
vs. 2, P-value = 0.001), but it does not reach statistical 
significant  differences  for  studies  analysing  GSTT1 
and GSTP1 polymorphisms (P-value = 0.685 and 0.147 
respectively) [Table 2].   
Logistic regression analysis for studies examined 
any GST polymorphism revealed that the OR for pos-
itive  outcome,  when  comparing  studies  with  1-3 
polymorphisms  tested  to  studies  with  more  than  3 
polymorphisms  tested,  was  3.906  (95%  CI,  1.506  to 
10.204, P-value = 0.005) after adjustment for sample 
size. 
Association of outcome of studies, IF and cita-
tion frequency 
 There were no significant associations between 
the  impact  factor  (range:  0.0  –  17.157)  and  positive 
studies  or  studies  (P-value  =  0.415)  with  1-3  poly-
morphisms examined (P-value = 0.341) [Table 3]. 
 We failed to retrieve information about citation 
frequency  from  8  studies  [59,61,62,63,73,74,79,89]  . 
The median citations per year for the remaining 71 
studies was 1.67 (range: 0 – 17.33). Citations per year 
were not significantly associated with either the study 
outcome  (P-value  =  0.185)  or  the  number  of  poly-
morphisms tested (P-value = 0.986) [Table 3]. 
 
 
 
Table 1. Characteristics of eligible genetic association 
studies 
Characteristic  No of studies (%) 
Country of origin   
   USA  21 (26.5) 
   United Kingdom  10 (13) 
   Germany  6 (8) 
   India  5 (6) 
   South Korea  5 (6) 
   Other  32 (40.5) 
Type of cancer   
   Breast   15 (19) 
   Colorectal  14 (18) 
   Lung  12 (15) 
   Ovarian  10 (13) 
   Other  28 (35) 
Sample size   
   < 50 patients  6 (7.5) 
   50-150 patients  33 (42) 
   150-250 patients  18 (23) 
   250-500 patients  17 (21.5) 
   500-1000 patients  2 (2.5) 
   > 1000 patients  3 (3.5) 
No of polymorphisms examined   
   1-3 polymorphisms  39 (49) 
   > 3 polymorphisms  40 (51) 
Type of GST examined   
   GSTM1 present/null  54 (68) 
   GSTT1 present/null  46 (58) 
   GSTP1 Ile105Val  57 (72) 
   GSTP1 Ala114Val  7 (9) 
   GSTM3 A*/A* or A*/B* or B*/B*  2 (2.5) 
   GSTA1 A*/A* or A*/B* or B*/B*  1 (1) 
   GSTP1 Thr110Ser  1 (1) 
   GSTP1 Asp147Tyr  1 (1) 
   GSTO1 Ala140Asp  1 (1) 
   GSTO2 Asn142Asp  1 (1) 
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Table 2. Outcome of eligible studies (positive-negative) according to number of polymorphisms tested 
Polymorphisms  No of studies (%)  P-value 
Positive outcome (%)  Negative outcome (%) 
any GST analysed       
 1-3 polymorphisms tested  29 (74)  10 (26)  0.004 
 > 3 polymorphisms tested  17 (42.5)  23 (57.5)   
GSTM1 present/null       
 1-3 polymorphisms tested  13 (48)  14 (52)  0.001 
 > 3 polymorphisms tested  2 (7)  25 (93)   
GSTT1 present/null       
 1-3 polymorphisms tested  4 (19)  17 (81)  0.685 
 > 3 polymorphisms tested  6 (24)  19 (76)   
GSTP1 Ile105Val       
 1-3 polymorphisms tested 
 > 3 polymorphisms tested 
11 (46) 
9 (27) 
13 (54) 
24 (73) 
0.147 
GSTP1 Ala114Val       
 1-3 polymorphisms tested  1 (100)  0 (0)  0.286 
 > 3 polymorphisms tested  1 (17)  5 (83)   
 
Table 3. Impact factor and Citations per Year in studies regarding outcome and number of polymorphisms 
 
  
Impact Factor  Citations Per Year 
Mean (+/- SD)  Median (range)  P-value   Mean +/- SD  Median (range)  P-value 
Any GST tested             
   Positive outcome  4.848 (4.170)  4.154 (0.0 – 17.157)    3.62 (4.24)  2.00 (0 – 17.33)   
   Negative outcome  5.099 (5.431)  3.508 (0.0 – 17.157)  0.415  2.40 (3.14)  1.17 (0 – 11.67)  0.185 
   1-3 polymorphisms tested  3.855 (2.743)  3.551 (0.0 – 14.933)    2.66 (3.22)  1.67 (0 -16.375)   
   > 3 polymorphisms tested  6.023 (5.879)  3.508 (0.0 – 17.157)  0.341  3.50 (4.31)  1.70 (0 – 17.33)  0.986 
GSTM1 present/null             
   Positive outcome   3.260 (2.421)  2.919 (0.0 – 7.514)    2.89 (2.65)  2.00 (0 – 8.33)   
   Negative outcome   5.212 (5.335)  3.508 (0.0 – 17.157)  0.369  3.32 (4.42)  1.67 (0 – 17.33)  0.736 
   1-3 polymorphisms tested  3.777 (3.138)  2.970 (0.0 – 14.933)    2.87 (3.61)  1.67 (0 – 16.375)   
   > 3 polymorphisms tested  5.563 (5.889)  2.970 (0.0 – 17.157)  0.522  3.51 (4.37)  2.00 (0 – 17.33)  0.893 
GSTT1 present/null             
   Positive outcome  5.224 (4.816)  3.883 (0.0 – 17.157)    2.39 (2.85)  1.14 (0 – 8.33)   
   Negative outcome  4.906 (5.138)  3.289 (0.0 – 17.157)  0.454  3.80 (4.54)  1.95 (0 – 17.33)  0.343 
   1-3 polymorphisms tested  3.876 (3.368)  3.069 (0.0 – 14.933)    3.17 (3.99)  1.67 (0 – 16.375)   
   > 3 polymorphisms tested  5.899 (5.986)  3.508 (0.0 – 17.157)  0.420  3.74 (4.48)  2.40 (0 – 17.33)  0.854 
GSTP1 Ile105Val             
   Positive outcome  5.472 (3.966)  4.846 (1.932 – 17.157)    4.52 (5.44)  2.04 (0 – 17.33)   
   Negative outcome  5.107 (5.117)  3.508 (0.0 – 17.157)  0.162  2.71 (3.43)  1.38 (0 – 11.67)  0.238 
   1-3 polymorphisms tested  4.078 (3.010)  3.738 (0.0 -14.933)    3.05 (3.69)  1.78 (0 – 16.375)   
   > 3 polymorphisms tested  6.077 (5.532)  3.551 (0,843 – 17.157) 
 
0.352  3.51 (4.64)  1.25 (0 – 17.33)  0.461 
 
 
Discussion 
To our knowledge, this is the first study exam-
ined the potential role of number of polymorphisms 
tested on publication bias. We found that the positive 
outcome  for  a  given  polymorphism  might  be  over 
reported across genetic association studies analysing a 
small  number  of  polymorphisms  (n  =  1-3)  when 
compared  to  studies  analysing  the  same  polymor-
phism  within  a  higher  number  of  polymorphisms. 
This  was  particularly  evident  for  GSTM1  polymor-
phism. We, therefore, propose a new subtype of pub-
lication bias in genetic association studies regarding 
the number of polymorphisms tested. Thereafter pos-Int. J. Med. Sci. 2011, 8 
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itive results for genetic association studies analysing a 
small number of polymorphisms (n = 1-3) should be 
evaluated cautiously and considered at a lower level 
of evidence. 
There are several possible explanations for this 
finding.  First,  the  pressure  for  publication  among 
authors and the competition for acceptance in journals 
are fierce [3,4] and may lead the authors to perform 
studies  with  few  polymorphisms,  which  need  less 
time to complete, and to submit for publication only 
those with positive outcome. Researchers are gener-
ally more enthusiastic about projects that have posi-
tive results and are more likely to complete them and 
submit them for publication [4]. On the other hand, 
authors  of  studies  with  negative  results  are  disap-
pointed due to the feeling that null papers are typi-
cally given low publication priority scores and may 
not be accepted for publication [92]. Moreover, it is 
possible that reviewer’s and editor’s decision about 
publication are influenced by positive findings [2,3,4].  
An additional potential explanation for publica-
tion bias is that positive studies are more possible to 
be published in journals with higher IF [3,5]. None-
theless  ,  when  we  investigated  this  theory  by  com-
paring the IF from journals published positive studies 
versus those published negative we found no signifi-
cant association between IF and positive studies. We 
further tried to investigate the magnitude of the re-
ported publication bias on scientific knowledge. Since 
there is no way to measure the impact of published 
articles on medical knowledge we may estimate their 
impact indirectly by calculating how frequently other 
authors cite them. Our results are encouraging since 
we found that studies with positive results or with 1-3 
polymorphisms  were  not  cited  more  frequently 
compared with studies with negative results or with > 
3 polymorphisms. In literature, there are controver-
sies concerning the citation frequency among positive 
or negative studies. Previous studies in other medical 
fields  demonstrated  that  trials  with  a  positive  out-
come were cited significantly more often than trials 
with a negative outcome [6,7] while other studies find 
no association [93].  
We further documented that studies analysing a 
low number or a higher number of polymorphisms 
has the same probability to be published in impact 
factor journals. 
Biologists, researchers and physicians are actu-
ally  called  to  deal  with  translational  medicine  re-
search  manuscripts  in  their  daily  life.  However,  no 
parameters are actually available to orient them in a 
correct interpretation of potential misleading sources 
of literature-bias. The existence of such type of bias in 
genetic  association  studies  might  lead  to  incorrect 
conclusions about the usefulness of certain polymor-
phisms  as  prognostic  genetic  markers.  It  may  also 
have  direct  impact  in  medical  research  by  guiding 
researchers and funding sources in investigating in-
significant genes. It is, therefore, extremely important 
to minimize this bias in medical literature since it may 
lead to severe decision-making consequences both in 
clinical  and  pharmacological  development  settings. 
We,  therefore,  propose  that  researchers  should  per-
form  studies  that  examine  many  polymorphisms; 
however, for researchers who investigate one or a few 
SNPs, they should publish their study regardless of 
the outcome. It should be emphasized, however, that 
the  transition  from  single  SNP  studies  to  ge-
nome-wide  association  studies  (GWAS)––of  cohorts 
sufficiently large in size so as to guarantee ample sta-
tistical  power––represents  a  new  era  in  human  ge-
netics, which has now arrived and offers an oppor-
tunity to overcome biases related to under-powered 
SNP studies on cohorts that are too small. There are 
several drawbacks in the study which should be dis-
cussed. First, one can oppose that there is problem in 
generalizing  these  data  to  all  genetic  association 
studies.  This  is  correct.  Anyhow,  since  our  study 
outcomes were pre-specified and include all available 
evidence (79 studies) in this topic, our data are ex-
tremely possible to be solid enough to  support our 
hypotheses. Confirmatory studies on polymorphisms 
of  other  genes  are  anyhow  needed  to  depict  the 
strength of our hypothesis. Second, one could argue 
that the observed higher rate of positive outcome in 
studies with small numbers of polymorphisms might 
reflect the investigation of SNPs that have been found 
to  be  “positive”  in  previous  studies.  Moreover,  be-
cause several thresholds for the definition of statistical 
significance on genetic association studies have been 
proposed  [94]  whereas  no  consensus  has  been 
reached, there is the risk that some of these studies 
could be misclassified as “positive. 
Conclusion: publication bias due to the number 
of polymorphism tested is a potential threat in medi-
cal literature. Positive results for genetic association 
studies analysing a small number of polymorphisms 
(n = 1-3) should be evaluated cautiously and consid-
ered  at  a  lower  level  of  evidence.  Biologists,  re-
searchers  and  physicians  dealing  with  translational 
medicine research should be aware of this potential 
threat for “false-positive” reports. 
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